The Experts below are selected from a list of 315 Experts worldwide ranked by ideXlab platform
Jenkun Lin - One of the best experts on this subject based on the ideXlab platform.
-
pu erh tea polysaccharides decrease blood sugar by inhibition of α Glucosidase activity in vitro and in mice
Food & Function, 2015Co-Authors: Yeatyz Deng, Shoeiyn Linshiau, Liefen Shyur, Jenkun LinAbstract:Type 2 diabetes is mainly induced by environmental factors such as being overweight, decreased physical activity and inbalanced energy metabolism, such as pancreatic beta-cell dysfunction and peripheral insulin resistance. Acarbose, a microbial carbohydrate and an Alpha-Glucosidase Inhibitor, is currently a useful agent for attenuating type 2 diabetes. However, it is usually accompanied by many side effects, such as abdominal distention, flatulence, diarrhea and meteorism. These side effects may be caused by its strong inhibition of Alpha-amylase, leading to the accumulation of several undigested carbohydrates. The bacteria residing in the colon can further ferment the undigested carbohydrate to release gas. Finding a new Alpha-Glucosidase Inhibitor with a low Inhibitory effect on Alpha-amylase is highly anticipated. In this report we describe a group of carbohydrates found in pu-erh tea polysaccharide (PTPS) that can inhibit Alpha-Glucosidase but have less of an Inhibitory effect on Alpha-amylase. The preliminary experiments on mice indicate that PTPS might be better than acarbose at suppressing blood glucose after oral administration of a carbohydrate diet; it is recommended that further clinical trials are required in type 2 diabetes in future studies.
Takashi Ibuka - One of the best experts on this subject based on the ideXlab platform.
-
Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice
International journal of molecular sciences, 2020Co-Authors: Junichi Kato, Yohei Shirakami, Taku Mizutani, Masaya Kubota, Hiroyasu Sakai, Takashi Ibuka, Masahito ShimizuAbstract:Type 2 diabetes mellitus and its related insulin resistance are known to increase the risk of cancer. Anti-diabetic agents can improve insulin resistance and may lead to the suppression of carcinogenesis. This study aimed to investigate the preventive effects of the Alpha-Glucosidase Inhibitor voglibose on the development of azoxymethane-induced colorectal pre-neoplastic lesions in obese and diabetic C57BL/KsJ-db/db mice. The direct effects of voglibose on the proliferation of colorectal cancer cells were also evaluated. Mice were injected with azoxymethane to induce colorectal pre-malignancy and were then administered drinking water with or without voglibose. At the end of the study, the administration of voglibose significantly suppressed the development of colorectal neoplastic lesions. In voglibose-treated mice, serum glucose levels, oxidative stress, as well as mRNA expression of the insulin-like growth factor-1 in the colon mucosa, were reduced. The proliferation of human colorectal cancer cells was not altered by voglibose. These results suggested that voglibose suppressed colorectal carcinogenesis in a diabetes- and obesity-related colorectal cancer model, presumably by improving inflammation via the reduction of oxidative stress and suppressing of the insulin-like growth factor/insulin-like growth factor-1 receptor axis in the colonic mucosa.
-
Alpha-Glucosidase Inhibitor use is associated with decreased colorectal neoplasia risk in patients with type 2 diabetes mellitus receiving colonoscopy: a retrospective study
Oncotarget, 2017Co-Authors: Yohei Horibe, Seiji Adachi, Tomohiko Ohno, Naoe Goto, Mitsuru Okuno, Midori Iwama, Osamu Yamauchi, Takao Kojima, Koshiro Saito, Takashi IbukaAbstract:The purpose of this study was to clarify the factors that influence the incidence of colorectal neoplasia in patients with type 2 diabetes mellitus (DM). Among a total of 1176 patients who underwent total colonoscopy at our hospital, we retrospectively analyzed 168 patients with type 2 DM. Univariate and multivariate logistic regression analyses were then performed to identify the risk factors associated with colorectal neoplasia. A multivariate analysis of these patients demonstrated that male gender (odds ratio [OR] = 4.04, 95% confidence interval [CI] = 1.67-10.37, p = 0.002), taking statins (OR = 4.59, 95% CI = 1.69-13.43, p = 0.003), taking Alpha Glucosidase Inhibitor (α-GI) (OR = 0.35, 95% CI = 0.13-0.87, p = 0.023) and taking low-dose aspirin (LDA) (OR = 0.32, 95% CI = 0.10-0.95, p = 0.040) were independent factors associated with an increased (male gender and statins) or decreased (α-GI and LDA) risk of colorectal neoplasia. While male gender and taking statins are risk factors, taking α-GI as well as LDA may reduce the risk of colorectal neoplasia in patients with type2 DM.
-
Alpha Glucosidase Inhibitor use is associated with decreased colorectal neoplasia risk in patients with type 2 diabetes mellitus receiving colonoscopy a retrospective study
Oncotarget, 2017Co-Authors: Yohei Horibe, Seiji Adachi, Tomohiko Ohno, Naoe Goto, Mitsuru Okuno, Midori Iwama, Osamu Yamauchi, Takao Kojima, Koshiro Saito, Takashi IbukaAbstract:// Yohei Horibe 1 , Seiji Adachi 1 , Tomohiko Ohno 1 , Naoe Goto 1 , Mitsuru Okuno 1 , Midori Iwama 1 , Osamu Yamauchi 1 , Takao Kojima 1 , Koshiro Saito 1 , Takashi Ibuka 2, 3 , Ichiro Yasuda 2 , Hiroshi Araki 3 , Hisataka Moriwaki 3 and Masahito Shimizu 3 1 Department of Gastroenterology and Internal Medicine, Gihoku Kosei Hospital, Yamagata, 501-2105, Japan 2 Division for Regional Cancer Control, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan 3 Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan Correspondence to: Seiji Adachi, email: sadachi-gif@umin.ac.jp Keywords: type 2 diabetes mellitus, colorectal neoplasia, risk factor Received: October 13, 2016 Accepted: May 03, 2017 Published: June 08, 2017 ABSTRACT Purpose: The purpose of this study was to clarify the factors that influence the incidence of colorectal neoplasia in patients with type 2 diabetes mellitus (DM). Study Design and Setting: Among a total of 1176 patients who underwent total colonoscopy at our hospital, we retrospectively analyzed 168 patients with type 2 DM. Univariate and multivariate logistic regression analyses were then performed to identify the risk factors associated with colorectal neoplasia. Results: A multivariate analysis of these patients demonstrated that male gender (odds ratio [OR] = 4.04, 95% confidence interval [CI] = 1.67–10.37, p = 0.002), taking statins (OR = 4.59, 95% CI = 1.69–13.43, p = 0.003), taking Alpha Glucosidase Inhibitor (α-GI) (OR = 0.35, 95% CI = 0.13–0.87, p = 0.023) and taking low-dose aspirin (LDA) (OR = 0.32, 95% CI = 0.10–0.95, p = 0.040) were independent factors associated with an increased (male gender and statins) or decreased (α-GI and LDA) risk of colorectal neoplasia. Conclusions: While male gender and taking statins are risk factors, taking α-GI as well as LDA may reduce the risk of colorectal neoplasia in patients with type2 DM.
Kazufumi Nakamura - One of the best experts on this subject based on the ideXlab platform.
-
The effect of luseogliflozin and Alpha-Glucosidase Inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial.
BMJ open, 2019Co-Authors: Kentaro Ejiri, Toru Miyoshi, Kazufumi Nakamura, Satoru Sakuragi, Mitsuru Munemasa, Seiji Namba, Atsushi Takaishi, Hiroshi ItoAbstract:Introduction Type 2 diabetes mellitus (T2DM) is a strong risk factor for coronary artery disease and heart failure, particularly heart failure with preserved ejection fraction (HFpEF). The aim of the ongoing MUSCAT-HF (It stands for Prospective Comparison of Luseogliflozin and Alpha-Glucosidase on the Management of Diabetic Patients with Chronic Heart Failure and Preserved Ejection Fraction) trial is to evaluate the efficacy of luseogliflozin, a sodium-glucose cotransporter 2 (SGLT2) Inhibitor, versus voglibose, an Alpha-Glucosidase Inhibitor, using brain natriuretic peptide (BNP) as the index of therapeutic effect in T2DM patients with HFpEF. Methods and analysis A total of 190 patients with T2DM and HFpEF (ejection fraction >45%) who are drug-naive or taking any anti-diabetic agents will be randomised (1:1) to receive luseogliflozin 2.5 mg one time per day or voglibose 0.2 mg three times per day. The patients will be stratified by age ( Ethics and dissemination The study has been approved by the ethics committee and the patients will be included after informed consent. The results will be submitted for publication in peer-reviewed journals. Trial registration number UMIN000018395
-
comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes results of the 3d trial
Cardiovascular Diabetology, 2015Co-Authors: Kazufumi Nakamura, Toru Miyoshi, Hajime Kihara, Kenei Shimada, Shota Fukuda, Tsutomu Takagi, Kumiko Hirata, Junichi Yoshikawa, Hiroshi ItoAbstract:Background Left ventricular (LV) diastolic dysfunction is frequently observed in patients with type 2 diabetes. Dipeptidyl peptidase-4 Inhibitor (DPP-4i) attenuates postprandial hyperglycemia (PPH) and may have cardio-protective effects. It remains unclear whether DPP-4i improves LV diastolic function in patients with type 2 diabetes, and, if so, it is attributable to the attenuation of PPH or to a direct cardiac effect of DPP-4i. We compared the effects of the DPP-4i, sitagliptin, and the Alpha-Glucosidase Inhibitor, voglibose, on LV diastolic function in patients with type 2 diabetes.
-
dpp 4 Inhibitor and Alpha Glucosidase Inhibitor equally improve endothelial function in patients with type 2 diabetes edge study
Cardiovascular Diabetology, 2014Co-Authors: Kazufumi Nakamura, Toru Miyoshi, Hajime Kihara, Kenei Shimada, Shota Fukuda, Kyoko Watanabe, Tsutomu Takagi, Kei Yunoki, Kumiko Hirata, Junichi YoshikawaAbstract:Alpha Glucosidase Inhibitor (GI) attenuates postprandial hyperglycemia (PPH) and reduces the risk of cardiovascular events in patients with impaired glucose tolerance or type 2 diabetes. Dipeptidyl peptidase 4 (DPP-4) Inhibitors also attenuate PPH. PPH is one of the factors leading to endothelial dysfunction which is an early event in the pathogenesis of atherosclerosis. Furthermore, DPP-4 Inhibitors protect endothelial function through a GLP-1-dependent mechanism. However, the impact of these two types of drugs on endothelial dysfunction in patients with type 2 diabetes has not been fully elucidated. We compared the effects of sitagliptin, a DPP-4 Inhibitor, and voglibose, an Alpha GI, on endothelial function in patients with diabetes. We conducted a randomized prospective multicenter study in 66 patients with type 2 diabetes who did not achieve the treatment goal with sulfonylurea, metformin or pioglitazone treatment; 31 patients received sitagliptin treatment and 35 patients, voglibose treatment. The flow-mediated dilatation (FMD) of the brachial artery was measured in the fasting state at baseline and after 12 weeks of treatment. The primary endpoint was a change in FMD (ΔFMD) from the baseline to the end of follow-up. The effects of sitagliptin and voglibose on FMD were assessed by ANCOVA after adjustment for the baseline FMD, age, sex, current smoking, diabetes duration and body mass index. Secondary efficacy measures included changes in HbA1c, GIP, GLP-1, C-peptide, CD34, lipid profile, oxidative stress markers, inflammatory markers and eGFR and any adverse events. ΔFMD was significantly improved after 12 weeks of treatment in both groups, and there was no significant difference in ΔFMD between the two groups. There were no significant differences in changes in HbA1c, GIP, GLP-1, C-peptide, lipid profile, oxidative stress marker, inflammatory marker and eGFR between the two groups. Compared with voglibose, sitagliptin significantly increased the circulating CD34, a marker of endothelial progenitor cells. Adverse events were observed in 5 patients in only the voglibose group (diarrhea 1, nausea 1, edema 2 and abdominal fullness 1). Sitagliptin improved endothelial dysfunction just as well as voglibose in patients with type 2 diabetes. Sitagliptin had protective effects on endothelial function without adverse events. registered at http://www.umin.ac.jp/ctrj/ under UMIN000003951
Hiroshi Ito - One of the best experts on this subject based on the ideXlab platform.
-
The effect of luseogliflozin and Alpha-Glucosidase Inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial.
BMJ open, 2019Co-Authors: Kentaro Ejiri, Toru Miyoshi, Kazufumi Nakamura, Satoru Sakuragi, Mitsuru Munemasa, Seiji Namba, Atsushi Takaishi, Hiroshi ItoAbstract:Introduction Type 2 diabetes mellitus (T2DM) is a strong risk factor for coronary artery disease and heart failure, particularly heart failure with preserved ejection fraction (HFpEF). The aim of the ongoing MUSCAT-HF (It stands for Prospective Comparison of Luseogliflozin and Alpha-Glucosidase on the Management of Diabetic Patients with Chronic Heart Failure and Preserved Ejection Fraction) trial is to evaluate the efficacy of luseogliflozin, a sodium-glucose cotransporter 2 (SGLT2) Inhibitor, versus voglibose, an Alpha-Glucosidase Inhibitor, using brain natriuretic peptide (BNP) as the index of therapeutic effect in T2DM patients with HFpEF. Methods and analysis A total of 190 patients with T2DM and HFpEF (ejection fraction >45%) who are drug-naive or taking any anti-diabetic agents will be randomised (1:1) to receive luseogliflozin 2.5 mg one time per day or voglibose 0.2 mg three times per day. The patients will be stratified by age ( Ethics and dissemination The study has been approved by the ethics committee and the patients will be included after informed consent. The results will be submitted for publication in peer-reviewed journals. Trial registration number UMIN000018395
-
comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes results of the 3d trial
Cardiovascular Diabetology, 2015Co-Authors: Kazufumi Nakamura, Toru Miyoshi, Hajime Kihara, Kenei Shimada, Shota Fukuda, Tsutomu Takagi, Kumiko Hirata, Junichi Yoshikawa, Hiroshi ItoAbstract:Background Left ventricular (LV) diastolic dysfunction is frequently observed in patients with type 2 diabetes. Dipeptidyl peptidase-4 Inhibitor (DPP-4i) attenuates postprandial hyperglycemia (PPH) and may have cardio-protective effects. It remains unclear whether DPP-4i improves LV diastolic function in patients with type 2 diabetes, and, if so, it is attributable to the attenuation of PPH or to a direct cardiac effect of DPP-4i. We compared the effects of the DPP-4i, sitagliptin, and the Alpha-Glucosidase Inhibitor, voglibose, on LV diastolic function in patients with type 2 diabetes.
Yohei Horibe - One of the best experts on this subject based on the ideXlab platform.
-
Alpha-Glucosidase Inhibitor use is associated with decreased colorectal neoplasia risk in patients with type 2 diabetes mellitus receiving colonoscopy: a retrospective study
Oncotarget, 2017Co-Authors: Yohei Horibe, Seiji Adachi, Tomohiko Ohno, Naoe Goto, Mitsuru Okuno, Midori Iwama, Osamu Yamauchi, Takao Kojima, Koshiro Saito, Takashi IbukaAbstract:The purpose of this study was to clarify the factors that influence the incidence of colorectal neoplasia in patients with type 2 diabetes mellitus (DM). Among a total of 1176 patients who underwent total colonoscopy at our hospital, we retrospectively analyzed 168 patients with type 2 DM. Univariate and multivariate logistic regression analyses were then performed to identify the risk factors associated with colorectal neoplasia. A multivariate analysis of these patients demonstrated that male gender (odds ratio [OR] = 4.04, 95% confidence interval [CI] = 1.67-10.37, p = 0.002), taking statins (OR = 4.59, 95% CI = 1.69-13.43, p = 0.003), taking Alpha Glucosidase Inhibitor (α-GI) (OR = 0.35, 95% CI = 0.13-0.87, p = 0.023) and taking low-dose aspirin (LDA) (OR = 0.32, 95% CI = 0.10-0.95, p = 0.040) were independent factors associated with an increased (male gender and statins) or decreased (α-GI and LDA) risk of colorectal neoplasia. While male gender and taking statins are risk factors, taking α-GI as well as LDA may reduce the risk of colorectal neoplasia in patients with type2 DM.
-
Alpha Glucosidase Inhibitor use is associated with decreased colorectal neoplasia risk in patients with type 2 diabetes mellitus receiving colonoscopy a retrospective study
Oncotarget, 2017Co-Authors: Yohei Horibe, Seiji Adachi, Tomohiko Ohno, Naoe Goto, Mitsuru Okuno, Midori Iwama, Osamu Yamauchi, Takao Kojima, Koshiro Saito, Takashi IbukaAbstract:// Yohei Horibe 1 , Seiji Adachi 1 , Tomohiko Ohno 1 , Naoe Goto 1 , Mitsuru Okuno 1 , Midori Iwama 1 , Osamu Yamauchi 1 , Takao Kojima 1 , Koshiro Saito 1 , Takashi Ibuka 2, 3 , Ichiro Yasuda 2 , Hiroshi Araki 3 , Hisataka Moriwaki 3 and Masahito Shimizu 3 1 Department of Gastroenterology and Internal Medicine, Gihoku Kosei Hospital, Yamagata, 501-2105, Japan 2 Division for Regional Cancer Control, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan 3 Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan Correspondence to: Seiji Adachi, email: sadachi-gif@umin.ac.jp Keywords: type 2 diabetes mellitus, colorectal neoplasia, risk factor Received: October 13, 2016 Accepted: May 03, 2017 Published: June 08, 2017 ABSTRACT Purpose: The purpose of this study was to clarify the factors that influence the incidence of colorectal neoplasia in patients with type 2 diabetes mellitus (DM). Study Design and Setting: Among a total of 1176 patients who underwent total colonoscopy at our hospital, we retrospectively analyzed 168 patients with type 2 DM. Univariate and multivariate logistic regression analyses were then performed to identify the risk factors associated with colorectal neoplasia. Results: A multivariate analysis of these patients demonstrated that male gender (odds ratio [OR] = 4.04, 95% confidence interval [CI] = 1.67–10.37, p = 0.002), taking statins (OR = 4.59, 95% CI = 1.69–13.43, p = 0.003), taking Alpha Glucosidase Inhibitor (α-GI) (OR = 0.35, 95% CI = 0.13–0.87, p = 0.023) and taking low-dose aspirin (LDA) (OR = 0.32, 95% CI = 0.10–0.95, p = 0.040) were independent factors associated with an increased (male gender and statins) or decreased (α-GI and LDA) risk of colorectal neoplasia. Conclusions: While male gender and taking statins are risk factors, taking α-GI as well as LDA may reduce the risk of colorectal neoplasia in patients with type2 DM.